Catheter Precision, Inc Receives Additional Patents for LockeT in Great Britain and the European Market
Portfolio Pulse from Benzinga Newsdesk
Catheter Precision, Inc. (NYSE:VTAK), a US-based medical device company, has been granted two new patents in Great Britain and the European Market for its LockeT product line. These patents complement an earlier patent issued in Japan in 2023, bolstering the company's intellectual property portfolio in the electrophysiology sector.

January 02, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Catheter Precision, Inc. has received additional patents for its LockeT product line in Great Britain and the European Market, enhancing its IP position and potentially its competitive edge in the electrophysiology market.
The granting of additional patents typically strengthens a company's intellectual property rights, which can protect against competition and may lead to increased market share and revenues. For Catheter Precision, Inc., these patents in key markets like Great Britain and the European Market are likely to enhance the company's value proposition to investors and could positively influence the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90